Details of Host Protein-DME Interaction (HOSPPI)
| General Information of Drug-Metabolizing Enzyme (DME ID: DME0015) | |||||
|---|---|---|---|---|---|
| DME Name | Cytochrome P450 3A7 (CYP3A7), Homo sapiens | DME Info | |||
| UniProt ID | |||||
| EC Number | EC: 1.14.14.1 (Click to Show/Hide the Complete EC Tree) | ||||
| Lineage | Species: Homo sapiens (Click to Show/Hide the Complete Species Lineage) | ||||
| Interactome | |||||
| Disease Specific Interactions between Host Protein and DME (HOSPPI) | |||||
|---|---|---|---|---|---|
| ICD Disease Classification 02 Neoplasms | |||||
| ICD-11: 2A00 Brain cancer | Click to Show/Hide the Full List of HOSPPI: 6 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Medulloblastoma | Significant hypomethylation | |||
| Interaction Name | DNMT-CYP3A7 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 1.79E-211; delta-beta: -3.39E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the CYP3A7 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Cytochrome P450 3A7. As a result, the interaction between DNMT and CYP3A7 can significantly affect the drug-metabolizing process of Cytochrome P450 3A7. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Brain neuroblastoma | Significant hypomethylation | |||
| Interaction Name | DNMT-CYP3A7 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 7.89E-16; delta-beta: -5.91E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the CYP3A7 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Cytochrome P450 3A7. As a result, the interaction between DNMT and CYP3A7 can significantly affect the drug-metabolizing process of Cytochrome P450 3A7. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Brain neuroepithelial tumour | Significant hypomethylation | |||
| Interaction Name | DNMT-CYP3A7 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 4.60E-05; delta-beta: -3.52E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the CYP3A7 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Cytochrome P450 3A7. As a result, the interaction between DNMT and CYP3A7 can significantly affect the drug-metabolizing process of Cytochrome P450 3A7. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Multilayered rosettes embryonal tumour | Significant hypomethylation | |||
| Interaction Name | DNMT-CYP3A7 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 1.67E-14; delta-beta: -5.66E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the CYP3A7 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Cytochrome P450 3A7. As a result, the interaction between DNMT and CYP3A7 can significantly affect the drug-metabolizing process of Cytochrome P450 3A7. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Diffuse midline glioma | Significant hypomethylation | |||
| Interaction Name | DNMT-CYP3A7 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 7.81E-19; delta-beta: -3.51E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the CYP3A7 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Cytochrome P450 3A7. As a result, the interaction between DNMT and CYP3A7 can significantly affect the drug-metabolizing process of Cytochrome P450 3A7. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Third ventricle chordoid glioma | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP3A7 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 2.25E-03; delta-beta: 3.75E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP3A7 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Cytochrome P450 3A7. As a result, the interaction between DNMT and CYP3A7 can significantly affect the drug-metabolizing process of Cytochrome P450 3A7. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2B30 Lymphoma | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Lymphoma | Moderate hypomethylation | |||
| Interaction Name | DNMT-CYP3A7 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypomethylation p-value: 5.72E-04; delta-beta: -2.57E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hypo-methylate the CYP3A7 gene, which leads to a moderatly increased expression of the drug-metabolizing enzyme Cytochrome P450 3A7. As a result, the interaction between DNMT and CYP3A7 can moderatly affect the drug-metabolizing process of Cytochrome P450 3A7. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2B5F Uterine carcinosarcoma | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Uterine carcinosarcoma | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP3A7 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 8.57E-04; delta-beta: 4.50E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP3A7 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Cytochrome P450 3A7. As a result, the interaction between DNMT and CYP3A7 can significantly affect the drug-metabolizing process of Cytochrome P450 3A7. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2B71 Gastric cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Gastric cancer | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP3A7 interaction | ||||
| The Methylation Level of Disease Section Compare with the Adjacent Tissue | Significant hypermethylation p-value: 3.56E-03; delta-beta: 5.58E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP3A7 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Cytochrome P450 3A7. As a result, the interaction between DNMT and CYP3A7 can significantly affect the drug-metabolizing process of Cytochrome P450 3A7. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue adjacent to the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2C12 Liver cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| Histone modification | |||||
| Histone methyltransferases (HMTs) | Liver cancer | Activation | |||
| Uniprot ID | |||||
| Interaction Name | HMTs-CYP3A7 interaction | [1] | |||
| Studied Cell Lines | HepG2 cell line | ||||
| Description | The Histone 3 lysine 4 dimethylation of CYP3A7 gene is reported to activate the transcriptional activity of the drug-metabolizing enzyme Cytochrome P450 3A7. As a result, the interaction between Histone methyltransferases (HMTs) and CYP3A7 can enhance the drug-metabolizing process of Cytochrome P450 3A7. | ||||
| ICD-11: 2C25 Lung cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Lung cancer | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP3A7 interaction | ||||
| The Methylation Level of Disease Section Compare with the Other Disease Section | Significant hypermethylation p-value: 2.09E-03; delta-beta: 1.22E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP3A7 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Cytochrome P450 3A7. As a result, the interaction between DNMT and CYP3A7 can significantly affect the drug-metabolizing process of Cytochrome P450 3A7. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
DME methylation in tissue other than the diseased tissue of patients
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2C73 Ovarian cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Ovarian cancer | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP3A7 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 8.39E-04; delta-beta: 4.89E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP3A7 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Cytochrome P450 3A7. As a result, the interaction between DNMT and CYP3A7 can significantly affect the drug-metabolizing process of Cytochrome P450 3A7. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2C82 Prostate cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Prostate cancer | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP3A7 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 2.05E-04; delta-beta: 4.97E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP3A7 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Cytochrome P450 3A7. As a result, the interaction between DNMT and CYP3A7 can significantly affect the drug-metabolizing process of Cytochrome P450 3A7. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2C90 Renal cell carcinoma | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Renal cell carcinoma | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP3A7 interaction | ||||
| The Methylation Level of Disease Section Compare with the Other Disease Section | Significant hypermethylation p-value: 3.47E-02; delta-beta: 4.96E-02 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP3A7 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Cytochrome P450 3A7. As a result, the interaction between DNMT and CYP3A7 can significantly affect the drug-metabolizing process of Cytochrome P450 3A7. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
DME methylation in tissue other than the diseased tissue of patients
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD Disease Classification 05 Endocrine/nutritional/metabolic diseases | |||||
| ICD-11: 5B81 Obesity | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Obesity | Significant hypomethylation | |||
| Interaction Name | DNMT-CYP3A7 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 2.29E-16; delta-beta: -5.37E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the CYP3A7 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Cytochrome P450 3A7. As a result, the interaction between DNMT and CYP3A7 can significantly affect the drug-metabolizing process of Cytochrome P450 3A7. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| References | |||||
|---|---|---|---|---|---|
| 1 | Effects of pargyline on histone methylation in promoter and enhancer regions and transcription of CYP3A4/3A7. Yao Xue Xue Bao. 2017 Jan;52(1):91-8. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.